The class IIa HDAC inhibitor (TMP195) has been shown in a metastatic breast cancer model to induce recruitment and differentiation of phagocytic macrophages, reducing primary tumor burden and incidence of lung metastasis (125). This evidence concerns the gene HDAC9 and neoplasm.